The Structural Genomics Consortium, with grant support from the Bill & Melinda Gates Foundation, is spearheading a project to develop pharma-quality medicinal chemistry capabilities in malaria and tuberculosis. The plan is to develop therapeutic assets for product development by Medicines for Malaria Venture and the Global Alliance for TB Drug Development.